1.30
                                            Redhill Biopharma Ltd Adr Aktie (RDHL) Neueste Nachrichten
RedHill Biopharma to appeal Nasdaq compliance notice - Investing.com
RedHill Biopharma to appeal Nasdaq compliance notice By Investing.com - Investing.com South Africa
RDHL appeals Nasdaq notice; 180-day extension possible - Stock Titan
RedHill Biopharma Receives Nasdaq Staff Determination Notification - Benzinga
RedHill Biopharma Receives Nasdaq Staff Determination Notification - Barchart.com
RedHill's Talicia® Secures $4 Million Strategic Investment and U.S. Co-Commercialization Partnership Deal - PR Newswire
CID Holdco Inc (DAIC): What Does Valuation Ratios Tell Us? - fostersleader.com
Lixte Biotechnology Holdings Inc (LIXT): What Technical Indicators Show - fostersleader.com
RedHill Biopharma Signs New $1.8 Million Plus Sales Royalties Middle East Deal For Talicia® - Sahm
RedHill Biopharma stock surges after court upholds $10M judgment - Investing.com
RedHill Biopharma stock surges after court upholds $10M judgment By Investing.com - Investing.com South Africa
Is RDHL Poised for Rebound? Analyzing Financial Moves - StocksToTrade
RedHill Wins New York Supreme Court Appeal, Upholding $10 Million Summary Judgment Against Kukbo - Sahm
RedHill Biopharma Announces First Half 2025 Financial Results and Operational Highlights - Placera.se
RedHill Received Talicia® Licensing Payments Totaling $1.1 Million - PR Newswire
RedHill Biopharma receives Nasdaq extension to regain compliance by October - Investing.com South Africa
Redhill Biopharma stock soars after FDA provides positive pathway for Crohn’s drug - Investing.com India
RedHill-Supported Medscape H. Pylori Educational Program to Launch at Major Gastroenterology Congress - Finansavisen
RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency - PR Newswire
Redhill Biopharma stock hits 52-week low at $1.72 amid market challenges - Investing.com India
Redhill Biopharma stock hits 52-week low at $2.47 amid steep annual decline - Investing.com
RedHill Biopharma targets UK approval for H. pylori therapy - Investing.com
Redhill Biopharma stock hits 52-week low at $3 amid steep annual decline - Investing.com
Hyloris secures global rights to RedHill's RHB-102 - Investing.com
RedHill's Talicia® Adds 8 Million Lives With Coverage by Humana®'s Part D Plan. Also, New Data Supporting Simplified Three-Times Daily Talicia Dosing Published - PR Newswire
Talicia® Launched in the United Arab Emirates - PR Newswire
RedHill Biopharma Announces Plan to Implement ADS Ratio Change - PR Newswire
RedHill Biopharma finalizes agreement to enhance cash position - Investing.com
RedHill Announces New USPTO Patent Grant for Talicia® for H. pylori Treatment Through 2042 - PR Newswire
Balancing Acidity: Exploring the Proton Pump Inhibitors Market - openPR.com
symbol__ Stock Quote Price and Forecast - CNN
RedHill Biopharma Announces Talicia Approved in the United Arab Emirates and First Commercial Order Outside the U.S. - Barchart.com
RedHill Biopharma Announces Registered Direct Offering and Warrant Exercise for $3.8 Million Gross Proceeds - Barchart.com
Phil and RedHill Biopharma Partner to Increase Access to Talicia® - Business Wire
Why Beyond Meat Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket - Benzinga
RedHill’s Aemcolo® Granted FDA QIDP 5-Year Exclusivity Extension - BioSpace
Extremely Robust COVID-19 Clinical Trial Pipeline With 420+ Key Companies Expected to Change the Pace of the COVID-19 Treatment - PR Newswire UK
RedHill presents New Talicia® and Movantik® data analyses at ACG 2022 - EurekAlert!
RedHill Biopharma and Gaelan Medical Enter Into License Agreement for Talicia® for the United Arab Emirates - PR Newswire
RedHill Biopharma Presents Analyses of Movantik Onset of Action and Symptom Improvement at DDW 2021 - BioSpace
RedHill's Partner Cosmo Pharmaceuticals Successfully Completes Phase 2 Study of Rifamycin SV-MMX 600mg in IBS-D - PR Newswire
RedHill Biopharma Extends Talicia® Unrestricted National and Regional Commercial Coverage to Over 40 Million Additional Americans - Stock Titan
RedHill Biopharma Announces FDA Approval of Talicia® for Treatment of H. pylori in Adults - GlobeNewswire
RedHill Biopharma: TALICIA Launch For H. Pylori In Sight - Investing.com
RedHill Biopharma's Drug Pipeline May Merit Substantial Upside, And Potential Catalysts Are On The Horizon - Seeking Alpha
REDHILL BIOPHAR/S ADR (NASDAQ:RDHL) had its Buy rating reiterated by HC Wainwright - marketexclusive.com
Technical Analysis of RedHill Biopharma Ltd. Sponsored ADR (NASDAQ:RDHL) - TradingView
RDHL Stock Price and Chart — NASDAQ:RDHL - TradingView
S&W Seed Company (SANW): How Does It Stack Up Against Its Peers? - Insider Monkey
Redhill Biopharma (RDHL) Stock Price, News & Analysis - MarketBeat
        In Yahoo öffnen
        |
        In Google öffnen
            |
            In Finviz öffnen
        |
        In MarketWatch öffnen
            |
            Öffnen Sie in EDGAR    
        |
        Offen in Reuters
    
    
                Kapitalisierung:
                 
                  | 
                Volumen (24h):
                 
            
         
                     
                             Holen Sie sich die Stockscreener-App
                    Holen Sie sich die Stockscreener-App
                